TGFB1 and non-small cell lung carcinoma: Therefore, if this TGF-β assessment’s techniques were validated and its relationship with relapse in interventional NSCLC were confirmed in other studies, we could conclude that patients presenting this biomarker in their viable tumor cells would benefit from some type of TGF-β inhibitor therapy in combination with ICIs.